Stryker invests USD 400 million in CMR: Truist cuts Stryker stock target to USD 310

Published on 10/26/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CMR alliance gives Stryker an exclusive acquisition option. Stryker stock costs EUR 276.10 on October 26, 2026, 0.36 percent above Xetra close.

Robotics and upcoming results

Stryker committed USD 400 million to CMR Surgical on October 12, 2026.
Second-quarter revenue reached USD 6.59 billion in 2026, up 9.40 percent year over year.
Stryker stock trades at EUR 276.10 at 12:00 p.m. CET at Lang & Schwarz on October 26, 2026, 0.36 percent above the Xetra close of October 23, 2026.
Third-quarter results are scheduled for October 29, 2026.

Pop-Art-Comic zeigt Chirurgen mit robotergestütztem OP-System in leuchtenden Farben — Pop-Art-Comic-Illustration einer farbenfrohen Roboterchirurgie-Szene verbildlicht anschaulich das Geschäftsfeld von Stryker Corp. US8636671013 heute, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) is investing approximately USD 400 million in CMR Surgical, securing an exclusive option to acquire the robotics company and exclusive U.S. sales rights for its Versius portfolio. The alliance was announced on October 12, 2026, according to Stryker.

Three moves shape Stryker

The company set the robotics direction on October 12, 2026, with the USD 400 million preferred equity investment and the option to acquire 100.00 percent of CMR Surgical. On October 6, 2026, Spencer Stiles was appointed chief executive officer effective January 1, 2027, while Kevin Lobo is set to become executive chair, according to FT.com. On July 30, 2026, Stryker reported second-quarter revenue of USD 6.59 billion, up 9.40 percent from the prior year, and adjusted earnings per share of USD 3.69 against a USD 3.49 consensus estimate, according to MarketBeat.

What does robotics add?

The transaction gives Stryker a route into soft-tissue robotic surgery without an immediate full acquisition. CMR Surgical will continue product development and commercialization outside the United States, while Stryker handles U.S. sales for Versius. The agreement is subject to regulatory approvals and customary closing conditions, so the acquisition option does not establish a timetable for a takeover.

Results arrive October 29

Stryker's third-quarter earnings call is scheduled for October 29, 2026, at 4:30 p.m. ET, according to the company's investor-relations calendar. The quarterly dividend of USD 0.88 per share is scheduled for payment on October 30, 2026, according to MarketBeat. Analysts cited by MarketBeat include Truist Financial, which cut its target from USD 340.00 to USD 310.00 on October 6, 2026, while retaining a hold rating.

Stock stays near the daily level

For investors, the next result will test whether the robotics expansion can sit alongside Stryker's recent operating growth. The stock was trading at EUR 276.10 at Lang & Schwarz on October 26, 2026 at 12:00 p.m. CET, plus 0.36 percent versus the Xetra close of October 23, 2026 at EUR 275.10. The primary listing is on the NYSE, where MarketBeat reported a market capitalization of USD 118.0 billion and a 12-month range of USD 267.00 to USD 389.33 as of October 26, 2026. The further course of trading is shown by the continuously updated real-time quote of Stryker Corp stock.